Novo Nordisk Diabetes Pen

Sanofi gets FDA approval for NovoLog insulin biosimilar

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children with diabetes mellitus.

Business Insider · 1d

FDA approves Sanofi biosimilar product for treatment of diabetes

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric

MarketWatch · 1d

FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

Agency Continues Efforts to Increase Access to Insulin Treatment Options SILVER SPRING, Md., /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus.

Healio1d

FDA approves subcutaneous Merilog for glycemic control in diabetes

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

12d

Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

2don MSN

Ozempic shown to reduce drinking in first trial in alcohol-use disorder

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

10d

Obesity drug sales surge at Novo Nordisk

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

Yahoo Finance10d

Novo Nordisk beats on Wegovy sales, expects slower 2025 growth

Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are ... first since Medicare included the company's blockbuster diabetes and weight-loss drugs on its negotiation list for ...

Insight News12d

Attorney General Keith Ellison secures $35 Novo Nordisk insulin for Minnesotans

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results